Loading…
Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways
Intraductal papillary neoplasms of the bile duct are still poorly characterized regarding (1) their molecular alterations during the development to invasive carcinomas, (2) their subtype stratification and (3) their biological behavior. We performed a multicenter study that analyzed these issues in...
Saved in:
Published in: | Modern pathology 2014-01, Vol.27 (1), p.73-86 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c538t-dfbc8f80d293f6848a4a1cda1334eacf86a89c16e99a2ae4659791641b8e82a03 |
---|---|
cites | cdi_FETCH-LOGICAL-c538t-dfbc8f80d293f6848a4a1cda1334eacf86a89c16e99a2ae4659791641b8e82a03 |
container_end_page | 86 |
container_issue | 1 |
container_start_page | 73 |
container_title | Modern pathology |
container_volume | 27 |
creator | Schlitter, Anna Melissa Born, Diana Bettstetter, Marcus Specht, Katja Kim-Fuchs, Corina Riener, Marc-Oliver Jeliazkova, Petia Sipos, Bence Siveke, Jens T Terris, Benoit Zen, Yoh Schuster, Tibor Höfler, Heinz Perren, Aurel Klöppel, Günter Esposito, Irene |
description | Intraductal papillary neoplasms of the bile duct are still poorly characterized regarding (1) their molecular alterations during the development to invasive carcinomas, (2) their subtype stratification and (3) their biological behavior. We performed a multicenter study that analyzed these issues in a large European cohort. Intraductal papillary neoplasms of the bile duct from 45 patients were graded and subtyped using mucin markers and CDX2. In addition, tumors were analyzed for common oncogenic pathways, and the findings were correlated with subtype and grade. Data were compared with those from 22 extra- and intrahepatic cholangiocarcinomas. Intraductal papillary neoplasms showed a development from preinvasive low- to high-grade intraepithelial neoplasia to invasive carcinoma. Molecular and immunohistochemical analysis revealed mutated KRAS, overexpression of TP53 and loss of p16 in low-grade intraepithelial neoplasia, whereas loss of SMAD4 was found in late phases of tumor development. Alterations of HER2, EGFR, β-catenin and GNAS were rare events. Among the subtypes, pancreato-biliary (36%) and intestinal (29%) were the most common, followed by gastric (18%) and oncocytic (13%) subtypes. Patients with intraductal papillary neoplasm of the bile duct showed a slightly better overall survival than patients with cholangiocarcinoma (hazard ratio (cholangiocarcinoma versus intraductal papillary neoplasm of the bile duct): 1.40; 95% confidence interval: 0.46–4.30; P=0.552). The development of biliary intraductal papillary neoplasms of the bile duct follows an adenoma-carcinoma sequence that correlates with the stepwise activation of common oncogenic pathways. Further large trials are needed to investigate and verify the finding of a better prognosis of intraductal papillary neoplasms compared with conventional cholangiocarcinoma. |
doi_str_mv | 10.1038/modpathol.2013.112 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490756820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0893395222036018</els_id><sourcerecordid>3171935891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c538t-dfbc8f80d293f6848a4a1cda1334eacf86a89c16e99a2ae4659791641b8e82a03</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EotvCF-CALHHhksV_kqyNuFQVlEqVuMDZ8jqT1pUdB4-zVb89jrZUiENPPszvPb-ZR8g7zracSfUppmG25TaFrWBcbjkXL8iGd5I1TKjuJdkwpWUjdSdOyCniHWO87ZR4TU6EVEJJ3m3I4Woq2Q6LKzbQ2c4-BJsf6ARpDhYj0jTScgt07wPQFftMscB87xHonNNNBkSfJloSdTY7P6VoqZ8OKRwAqUsx1mFMAdxSjema994-4BvyarQB4e3je0Z-ffv68-J7c_3j8uri_LpxnVSlGca9U6Nig9By7FWrbGu5GyyXsgXrRtVbpR3vQWsrLLR9p3ea9y3fK1DCMnlGPh59a9bfC2Ax0aODumTdcEHDW812Xa_Ein74D71LS55qukrtpKqQlpUSR8rlhJhhNHP2sZ7McGbWVsxTK2ZtxdRWquj9o_WyjzA8Sf7WUAF5BLCOphvI__z9nO2XowrqBQ--qtB5mBwMPoMrZkj-Ofkf7HGzvg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1473868293</pqid></control><display><type>article</type><title>Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways</title><source>Nature</source><creator>Schlitter, Anna Melissa ; Born, Diana ; Bettstetter, Marcus ; Specht, Katja ; Kim-Fuchs, Corina ; Riener, Marc-Oliver ; Jeliazkova, Petia ; Sipos, Bence ; Siveke, Jens T ; Terris, Benoit ; Zen, Yoh ; Schuster, Tibor ; Höfler, Heinz ; Perren, Aurel ; Klöppel, Günter ; Esposito, Irene</creator><creatorcontrib>Schlitter, Anna Melissa ; Born, Diana ; Bettstetter, Marcus ; Specht, Katja ; Kim-Fuchs, Corina ; Riener, Marc-Oliver ; Jeliazkova, Petia ; Sipos, Bence ; Siveke, Jens T ; Terris, Benoit ; Zen, Yoh ; Schuster, Tibor ; Höfler, Heinz ; Perren, Aurel ; Klöppel, Günter ; Esposito, Irene</creatorcontrib><description>Intraductal papillary neoplasms of the bile duct are still poorly characterized regarding (1) their molecular alterations during the development to invasive carcinomas, (2) their subtype stratification and (3) their biological behavior. We performed a multicenter study that analyzed these issues in a large European cohort. Intraductal papillary neoplasms of the bile duct from 45 patients were graded and subtyped using mucin markers and CDX2. In addition, tumors were analyzed for common oncogenic pathways, and the findings were correlated with subtype and grade. Data were compared with those from 22 extra- and intrahepatic cholangiocarcinomas. Intraductal papillary neoplasms showed a development from preinvasive low- to high-grade intraepithelial neoplasia to invasive carcinoma. Molecular and immunohistochemical analysis revealed mutated KRAS, overexpression of TP53 and loss of p16 in low-grade intraepithelial neoplasia, whereas loss of SMAD4 was found in late phases of tumor development. Alterations of HER2, EGFR, β-catenin and GNAS were rare events. Among the subtypes, pancreato-biliary (36%) and intestinal (29%) were the most common, followed by gastric (18%) and oncocytic (13%) subtypes. Patients with intraductal papillary neoplasm of the bile duct showed a slightly better overall survival than patients with cholangiocarcinoma (hazard ratio (cholangiocarcinoma versus intraductal papillary neoplasm of the bile duct): 1.40; 95% confidence interval: 0.46–4.30; P=0.552). The development of biliary intraductal papillary neoplasms of the bile duct follows an adenoma-carcinoma sequence that correlates with the stepwise activation of common oncogenic pathways. Further large trials are needed to investigate and verify the finding of a better prognosis of intraductal papillary neoplasms compared with conventional cholangiocarcinoma.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/modpathol.2013.112</identifier><identifier>PMID: 23828315</identifier><identifier>CODEN: MODPEO</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>692/420/755 ; 692/699/67/1504/1329/1326 ; 692/700/1750 ; Adult ; Aged ; Aged, 80 and over ; Bile Duct Neoplasms - chemistry ; Bile Duct Neoplasms - genetics ; Bile Duct Neoplasms - mortality ; Bile Duct Neoplasms - pathology ; bile duct tumors ; Bile ducts ; Bile Ducts, Intrahepatic - chemistry ; Bile Ducts, Intrahepatic - pathology ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - genetics ; Biopsy ; Cancer ; Carcinoma in Situ - chemistry ; Carcinoma in Situ - genetics ; Carcinoma in Situ - mortality ; Carcinoma in Situ - pathology ; Carcinoma, Intraductal, Noninfiltrating - chemistry ; Carcinoma, Intraductal, Noninfiltrating - genetics ; Carcinoma, Intraductal, Noninfiltrating - mortality ; Carcinoma, Intraductal, Noninfiltrating - pathology ; Cholangiocarcinoma ; Cholangiocarcinoma - chemistry ; Cholangiocarcinoma - genetics ; Cholangiocarcinoma - pathology ; Confidence intervals ; Cyclin-Dependent Kinase Inhibitor p16 - analysis ; Disease Progression ; DNA Mutational Analysis ; Europe ; Female ; GNAS ; Hospitals ; Humans ; Immunohistochemistry ; intraductal precursor lesion ; Kaplan-Meier Estimate ; KRAS ; Laboratory Medicine ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Neoplasm Grading ; Neoplasm Invasiveness ; original-article ; Papilloma - chemistry ; Papilloma - genetics ; Papilloma - mortality ; Papilloma - pathology ; Pathology ; Prognosis ; Proportional Hazards Models ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins - genetics ; Signal Transduction ; Survival analysis ; Time Factors ; Tumor Suppressor Protein p53 - analysis ; Tumors</subject><ispartof>Modern pathology, 2014-01, Vol.27 (1), p.73-86</ispartof><rights>2014 United States & Canadian Academy of Pathology</rights><rights>United States & Canadian Academy of Pathology 2014</rights><rights>Copyright Nature Publishing Group Jan 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c538t-dfbc8f80d293f6848a4a1cda1334eacf86a89c16e99a2ae4659791641b8e82a03</citedby><cites>FETCH-LOGICAL-c538t-dfbc8f80d293f6848a4a1cda1334eacf86a89c16e99a2ae4659791641b8e82a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23828315$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schlitter, Anna Melissa</creatorcontrib><creatorcontrib>Born, Diana</creatorcontrib><creatorcontrib>Bettstetter, Marcus</creatorcontrib><creatorcontrib>Specht, Katja</creatorcontrib><creatorcontrib>Kim-Fuchs, Corina</creatorcontrib><creatorcontrib>Riener, Marc-Oliver</creatorcontrib><creatorcontrib>Jeliazkova, Petia</creatorcontrib><creatorcontrib>Sipos, Bence</creatorcontrib><creatorcontrib>Siveke, Jens T</creatorcontrib><creatorcontrib>Terris, Benoit</creatorcontrib><creatorcontrib>Zen, Yoh</creatorcontrib><creatorcontrib>Schuster, Tibor</creatorcontrib><creatorcontrib>Höfler, Heinz</creatorcontrib><creatorcontrib>Perren, Aurel</creatorcontrib><creatorcontrib>Klöppel, Günter</creatorcontrib><creatorcontrib>Esposito, Irene</creatorcontrib><title>Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>Intraductal papillary neoplasms of the bile duct are still poorly characterized regarding (1) their molecular alterations during the development to invasive carcinomas, (2) their subtype stratification and (3) their biological behavior. We performed a multicenter study that analyzed these issues in a large European cohort. Intraductal papillary neoplasms of the bile duct from 45 patients were graded and subtyped using mucin markers and CDX2. In addition, tumors were analyzed for common oncogenic pathways, and the findings were correlated with subtype and grade. Data were compared with those from 22 extra- and intrahepatic cholangiocarcinomas. Intraductal papillary neoplasms showed a development from preinvasive low- to high-grade intraepithelial neoplasia to invasive carcinoma. Molecular and immunohistochemical analysis revealed mutated KRAS, overexpression of TP53 and loss of p16 in low-grade intraepithelial neoplasia, whereas loss of SMAD4 was found in late phases of tumor development. Alterations of HER2, EGFR, β-catenin and GNAS were rare events. Among the subtypes, pancreato-biliary (36%) and intestinal (29%) were the most common, followed by gastric (18%) and oncocytic (13%) subtypes. Patients with intraductal papillary neoplasm of the bile duct showed a slightly better overall survival than patients with cholangiocarcinoma (hazard ratio (cholangiocarcinoma versus intraductal papillary neoplasm of the bile duct): 1.40; 95% confidence interval: 0.46–4.30; P=0.552). The development of biliary intraductal papillary neoplasms of the bile duct follows an adenoma-carcinoma sequence that correlates with the stepwise activation of common oncogenic pathways. Further large trials are needed to investigate and verify the finding of a better prognosis of intraductal papillary neoplasms compared with conventional cholangiocarcinoma.</description><subject>692/420/755</subject><subject>692/699/67/1504/1329/1326</subject><subject>692/700/1750</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bile Duct Neoplasms - chemistry</subject><subject>Bile Duct Neoplasms - genetics</subject><subject>Bile Duct Neoplasms - mortality</subject><subject>Bile Duct Neoplasms - pathology</subject><subject>bile duct tumors</subject><subject>Bile ducts</subject><subject>Bile Ducts, Intrahepatic - chemistry</subject><subject>Bile Ducts, Intrahepatic - pathology</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Carcinoma in Situ - chemistry</subject><subject>Carcinoma in Situ - genetics</subject><subject>Carcinoma in Situ - mortality</subject><subject>Carcinoma in Situ - pathology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - chemistry</subject><subject>Carcinoma, Intraductal, Noninfiltrating - genetics</subject><subject>Carcinoma, Intraductal, Noninfiltrating - mortality</subject><subject>Carcinoma, Intraductal, Noninfiltrating - pathology</subject><subject>Cholangiocarcinoma</subject><subject>Cholangiocarcinoma - chemistry</subject><subject>Cholangiocarcinoma - genetics</subject><subject>Cholangiocarcinoma - pathology</subject><subject>Confidence intervals</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - analysis</subject><subject>Disease Progression</subject><subject>DNA Mutational Analysis</subject><subject>Europe</subject><subject>Female</subject><subject>GNAS</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>intraductal precursor lesion</subject><subject>Kaplan-Meier Estimate</subject><subject>KRAS</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Invasiveness</subject><subject>original-article</subject><subject>Papilloma - chemistry</subject><subject>Papilloma - genetics</subject><subject>Papilloma - mortality</subject><subject>Papilloma - pathology</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>ras Proteins - genetics</subject><subject>Signal Transduction</subject><subject>Survival analysis</subject><subject>Time Factors</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><subject>Tumors</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kU9v1DAQxS0EotvCF-CALHHhksV_kqyNuFQVlEqVuMDZ8jqT1pUdB4-zVb89jrZUiENPPszvPb-ZR8g7zracSfUppmG25TaFrWBcbjkXL8iGd5I1TKjuJdkwpWUjdSdOyCniHWO87ZR4TU6EVEJJ3m3I4Woq2Q6LKzbQ2c4-BJsf6ARpDhYj0jTScgt07wPQFftMscB87xHonNNNBkSfJloSdTY7P6VoqZ8OKRwAqUsx1mFMAdxSjema994-4BvyarQB4e3je0Z-ffv68-J7c_3j8uri_LpxnVSlGca9U6Nig9By7FWrbGu5GyyXsgXrRtVbpR3vQWsrLLR9p3ea9y3fK1DCMnlGPh59a9bfC2Ax0aODumTdcEHDW812Xa_Ein74D71LS55qukrtpKqQlpUSR8rlhJhhNHP2sZ7McGbWVsxTK2ZtxdRWquj9o_WyjzA8Sf7WUAF5BLCOphvI__z9nO2XowrqBQ--qtB5mBwMPoMrZkj-Ofkf7HGzvg</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Schlitter, Anna Melissa</creator><creator>Born, Diana</creator><creator>Bettstetter, Marcus</creator><creator>Specht, Katja</creator><creator>Kim-Fuchs, Corina</creator><creator>Riener, Marc-Oliver</creator><creator>Jeliazkova, Petia</creator><creator>Sipos, Bence</creator><creator>Siveke, Jens T</creator><creator>Terris, Benoit</creator><creator>Zen, Yoh</creator><creator>Schuster, Tibor</creator><creator>Höfler, Heinz</creator><creator>Perren, Aurel</creator><creator>Klöppel, Günter</creator><creator>Esposito, Irene</creator><general>Elsevier Inc</general><general>Nature Publishing Group US</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201401</creationdate><title>Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways</title><author>Schlitter, Anna Melissa ; Born, Diana ; Bettstetter, Marcus ; Specht, Katja ; Kim-Fuchs, Corina ; Riener, Marc-Oliver ; Jeliazkova, Petia ; Sipos, Bence ; Siveke, Jens T ; Terris, Benoit ; Zen, Yoh ; Schuster, Tibor ; Höfler, Heinz ; Perren, Aurel ; Klöppel, Günter ; Esposito, Irene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c538t-dfbc8f80d293f6848a4a1cda1334eacf86a89c16e99a2ae4659791641b8e82a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>692/420/755</topic><topic>692/699/67/1504/1329/1326</topic><topic>692/700/1750</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bile Duct Neoplasms - chemistry</topic><topic>Bile Duct Neoplasms - genetics</topic><topic>Bile Duct Neoplasms - mortality</topic><topic>Bile Duct Neoplasms - pathology</topic><topic>bile duct tumors</topic><topic>Bile ducts</topic><topic>Bile Ducts, Intrahepatic - chemistry</topic><topic>Bile Ducts, Intrahepatic - pathology</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Carcinoma in Situ - chemistry</topic><topic>Carcinoma in Situ - genetics</topic><topic>Carcinoma in Situ - mortality</topic><topic>Carcinoma in Situ - pathology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - chemistry</topic><topic>Carcinoma, Intraductal, Noninfiltrating - genetics</topic><topic>Carcinoma, Intraductal, Noninfiltrating - mortality</topic><topic>Carcinoma, Intraductal, Noninfiltrating - pathology</topic><topic>Cholangiocarcinoma</topic><topic>Cholangiocarcinoma - chemistry</topic><topic>Cholangiocarcinoma - genetics</topic><topic>Cholangiocarcinoma - pathology</topic><topic>Confidence intervals</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - analysis</topic><topic>Disease Progression</topic><topic>DNA Mutational Analysis</topic><topic>Europe</topic><topic>Female</topic><topic>GNAS</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>intraductal precursor lesion</topic><topic>Kaplan-Meier Estimate</topic><topic>KRAS</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Invasiveness</topic><topic>original-article</topic><topic>Papilloma - chemistry</topic><topic>Papilloma - genetics</topic><topic>Papilloma - mortality</topic><topic>Papilloma - pathology</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>ras Proteins - genetics</topic><topic>Signal Transduction</topic><topic>Survival analysis</topic><topic>Time Factors</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schlitter, Anna Melissa</creatorcontrib><creatorcontrib>Born, Diana</creatorcontrib><creatorcontrib>Bettstetter, Marcus</creatorcontrib><creatorcontrib>Specht, Katja</creatorcontrib><creatorcontrib>Kim-Fuchs, Corina</creatorcontrib><creatorcontrib>Riener, Marc-Oliver</creatorcontrib><creatorcontrib>Jeliazkova, Petia</creatorcontrib><creatorcontrib>Sipos, Bence</creatorcontrib><creatorcontrib>Siveke, Jens T</creatorcontrib><creatorcontrib>Terris, Benoit</creatorcontrib><creatorcontrib>Zen, Yoh</creatorcontrib><creatorcontrib>Schuster, Tibor</creatorcontrib><creatorcontrib>Höfler, Heinz</creatorcontrib><creatorcontrib>Perren, Aurel</creatorcontrib><creatorcontrib>Klöppel, Günter</creatorcontrib><creatorcontrib>Esposito, Irene</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schlitter, Anna Melissa</au><au>Born, Diana</au><au>Bettstetter, Marcus</au><au>Specht, Katja</au><au>Kim-Fuchs, Corina</au><au>Riener, Marc-Oliver</au><au>Jeliazkova, Petia</au><au>Sipos, Bence</au><au>Siveke, Jens T</au><au>Terris, Benoit</au><au>Zen, Yoh</au><au>Schuster, Tibor</au><au>Höfler, Heinz</au><au>Perren, Aurel</au><au>Klöppel, Günter</au><au>Esposito, Irene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2014-01</date><risdate>2014</risdate><volume>27</volume><issue>1</issue><spage>73</spage><epage>86</epage><pages>73-86</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><coden>MODPEO</coden><abstract>Intraductal papillary neoplasms of the bile duct are still poorly characterized regarding (1) their molecular alterations during the development to invasive carcinomas, (2) their subtype stratification and (3) their biological behavior. We performed a multicenter study that analyzed these issues in a large European cohort. Intraductal papillary neoplasms of the bile duct from 45 patients were graded and subtyped using mucin markers and CDX2. In addition, tumors were analyzed for common oncogenic pathways, and the findings were correlated with subtype and grade. Data were compared with those from 22 extra- and intrahepatic cholangiocarcinomas. Intraductal papillary neoplasms showed a development from preinvasive low- to high-grade intraepithelial neoplasia to invasive carcinoma. Molecular and immunohistochemical analysis revealed mutated KRAS, overexpression of TP53 and loss of p16 in low-grade intraepithelial neoplasia, whereas loss of SMAD4 was found in late phases of tumor development. Alterations of HER2, EGFR, β-catenin and GNAS were rare events. Among the subtypes, pancreato-biliary (36%) and intestinal (29%) were the most common, followed by gastric (18%) and oncocytic (13%) subtypes. Patients with intraductal papillary neoplasm of the bile duct showed a slightly better overall survival than patients with cholangiocarcinoma (hazard ratio (cholangiocarcinoma versus intraductal papillary neoplasm of the bile duct): 1.40; 95% confidence interval: 0.46–4.30; P=0.552). The development of biliary intraductal papillary neoplasms of the bile duct follows an adenoma-carcinoma sequence that correlates with the stepwise activation of common oncogenic pathways. Further large trials are needed to investigate and verify the finding of a better prognosis of intraductal papillary neoplasms compared with conventional cholangiocarcinoma.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><pmid>23828315</pmid><doi>10.1038/modpathol.2013.112</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0893-3952 |
ispartof | Modern pathology, 2014-01, Vol.27 (1), p.73-86 |
issn | 0893-3952 1530-0285 |
language | eng |
recordid | cdi_proquest_miscellaneous_1490756820 |
source | Nature |
subjects | 692/420/755 692/699/67/1504/1329/1326 692/700/1750 Adult Aged Aged, 80 and over Bile Duct Neoplasms - chemistry Bile Duct Neoplasms - genetics Bile Duct Neoplasms - mortality Bile Duct Neoplasms - pathology bile duct tumors Bile ducts Bile Ducts, Intrahepatic - chemistry Bile Ducts, Intrahepatic - pathology Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Biopsy Cancer Carcinoma in Situ - chemistry Carcinoma in Situ - genetics Carcinoma in Situ - mortality Carcinoma in Situ - pathology Carcinoma, Intraductal, Noninfiltrating - chemistry Carcinoma, Intraductal, Noninfiltrating - genetics Carcinoma, Intraductal, Noninfiltrating - mortality Carcinoma, Intraductal, Noninfiltrating - pathology Cholangiocarcinoma Cholangiocarcinoma - chemistry Cholangiocarcinoma - genetics Cholangiocarcinoma - pathology Confidence intervals Cyclin-Dependent Kinase Inhibitor p16 - analysis Disease Progression DNA Mutational Analysis Europe Female GNAS Hospitals Humans Immunohistochemistry intraductal precursor lesion Kaplan-Meier Estimate KRAS Laboratory Medicine Male Medical prognosis Medicine Medicine & Public Health Middle Aged Mutation Neoplasm Grading Neoplasm Invasiveness original-article Papilloma - chemistry Papilloma - genetics Papilloma - mortality Papilloma - pathology Pathology Prognosis Proportional Hazards Models Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Signal Transduction Survival analysis Time Factors Tumor Suppressor Protein p53 - analysis Tumors |
title | Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T22%3A55%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraductal%20papillary%20neoplasms%20of%20the%20bile%20duct:%20stepwise%20progression%20to%20carcinoma%20involves%20common%20molecular%20pathways&rft.jtitle=Modern%20pathology&rft.au=Schlitter,%20Anna%20Melissa&rft.date=2014-01&rft.volume=27&rft.issue=1&rft.spage=73&rft.epage=86&rft.pages=73-86&rft.issn=0893-3952&rft.eissn=1530-0285&rft.coden=MODPEO&rft_id=info:doi/10.1038/modpathol.2013.112&rft_dat=%3Cproquest_cross%3E3171935891%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c538t-dfbc8f80d293f6848a4a1cda1334eacf86a89c16e99a2ae4659791641b8e82a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1473868293&rft_id=info:pmid/23828315&rfr_iscdi=true |